Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: GlobalData | PRODUCT CODE: 2005397

Cover Image

PUBLISHER: GlobalData | PRODUCT CODE: 2005397

Industry Insights: GLP-1 Innovation Landscape 2026

PUBLISHED:
PAGES: 44 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 1950
PDF (Site License)
USD 2925
PDF (Global License)
USD 3900

Add to Cart

This report is part of a series on key trends which are currently affecting the consumer landscape. This report offers an analysis of the key GLP-1-driven retail and brand food and drinks innovation that are meeting consumer demand in this space.

GLP 1 drugs use (e.g., Ozempic, Wegovy) is rapidly expanding beyond treatments for diabetes and into mainstream weight management because they are effective at increasing satiety and reducing food intake, resulting in rapid weight loss. Usage is surging with global GLP-1 drug sales forecast to rise from $76 billion in 2025 to $162 billion by 2031. GLP-1 drugs change eating behavior, with users preferring smaller portions and nutrient-dense foods to supplement their reduced dietary intake. Retailers are moving fastest with new innovation in "GLP 1 friendly" food and ready meal ranges, formulated with high protein, high fiber, with balanced nutrient and vitamin content. Brands are reevaluating existing product formulations to boost GLP-1 friendly ingredients.

Scope

  • GLP-1 adoption is accelerating and becoming a major demand driver: Use is rising quickly, with the global market projected to grow from $76 billion (2025) to $161.9 billion (2031). GLP-1 pills will expand access, but injectables remain the main growth engine.
  • Food needs are shifting because GLP-1 changes eating behavior: Users eat less, feel full faster, and can be more sensitive to rich foods-creating demand for smaller, nutrient-dense portions that still deliver nutrition.
  • The side effects of GLP-1 drug use (nausea/constipation/diarrhea) open up space for tolerability-supporting products, particularly those with higher-fiber ingredients.
  • Retailers are moving faster in this space than brands with explicit GLP-1 ranges: UK retailers have launched "GLP-1 friendly" lines (portion-controlled, high protein/fiber, lower calorie, added micronutrients), setting a template for the market.
  • Brands are mostly taking a cautious approach: many manufacturers are quietly aligning with the needs of GLP-1 users (protein, nutrient density, smaller portions) rather than overtly targeting them.

Reasons to Buy

  • Understand how big the GLP-1-driven opportunity is, why it matters-and how fast it is scaling with a clear view of adoption and revenue momentum, to help size the commercial opportunity, inspire innovation ideas, and prioritize markets.
  • Discover who is most interested in GLP-I formulated food and drinks, what their formulation requirements are, and how this leads to concrete innovation opportunities.
  • Deep dive into what retailers are doing right now and why it matters-the playbook behind "Jab-uary" launches, how to present key on-pack messages to convert interest into sales, and what this signals for brands.
  • Understand what winning products need to deliver, where the whitespace is, why "real food" cues matter-and how to use portion control as part of final product delivery.
Product Code: GDCG260004HT

Table of Contents

Table of Contents

  • Executive Summary

1. Overview

  • GLP-1 Agonists Explained
  • GLP-1 GB and US User Numbers
  • GLP-1 Global Market Forecasts
  • GLP-1 Wegovy Pill Forecasts
  • Social Media Analytics
  • "Weight Management" Product Sales Forecasts

2. What are the Consumer Drivers?

3. Retail Innovation

4. Brand Innovation

5. GLP-1 Innovation

  • Takeaways

Appendix

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!